Introduction
The clinical syndrome of heart failure (HF) is associated with a wide spectrum of abnormalities of left ventricular (LV) structure and function, ranging from a normal LV chamber size with a preserved ejection fraction (EF), to severe LV chamber dilatation with a markedly reduced EF. Left ventricular EF is considered important with respect to classifying HF patients because of differing patient demographics, prognosis, as well as the response to HF therapies.
1 Current American HF guidelines divide the HF population into two separate groups of patients based on their LVEF:
2016 European Society of Cardiology (ESC) HF guidelines recognize this as a distinct group of HF and illustrates the need to better understand their underlying characteristics, pathophysiology, and treatment. 7 Given that the prevalence of patients with a mid-range LVEF (40-50%) is increasing in contemporary HF clinics, and given that there are no current management guidelines for this group of patients, we sought to determine the epidemiology, pathophysiology and clinical outcomes of HF patients with a mid-range EF (HFmrEF) by performing a case-control study of patients who were enrolled in the Washington University Heart Failure Registry. 8 Here we show that the epidemiology, pathophysiology and clinical outcomes of a contemporary group of patients with an LVEF between 40-50% are remarkably heterogeneous with respect to pathophysiology and clinical outcomes.
Methods

Patient demographics
We identified patients with a documented LVEF between 40-50% at the time of enrollment in the Washington University Heart Failure Registry (see the Supplementary material online, Table S1 ). The Washington University Heart Failure Registry was designed as a prospective registry of inpatients and outpatients with clinical evidence of HF irrespective of LVEF. All patients were enrolled in the registry from March 2010 to August 2013 without any selection bias. Detailed patient information was prospectively collected and patient vital status followed for 2 years after enrollment, as previously described. 8 For the purpose of the present analysis, the patients with an LVEF 40-50% are referred to as HFmrEF. In order to determine whether the LVEF at the time of enrollment was improved, worsened, or the same as a prior assessments of LVEF, we performed a retrospective chart review of the HFmrEF patients. The prior EFs were selected from the first documented echocardiogram for the diagnosis of HF. The HFmrEF patients whose EF was <40% prior to enrollment in the registry are referred to as "HFmrEF improved" and the HFmrEF patients whose EF was >50% prior to enrollment are referred to as "HFmrEF deteriorated". The HFmrEF patients whose EF was between 40-50% prior to enrollment are referred to as "HFmrEF unchanged".
Patients without a known prior EF were excluded from the analysis (n = 4). When available, prior outpatient echocardiographic assessment of LV function was preferentially used, rather than echocardiographic data acquired as an inpatient, in order to avoid any potential bias related to transient depression in LV function (e.g. during an acute episode of acute decompensated HF). Approval was obtained from the Washington University Institutional Review Board and the study conformed to the principles of the Declaration of Helsinki. All patients gave written, informed consent prior to participation.
Clinical outcomes
The clinical outcomes that were assessed included death, cardiac transplantation, HF hospitalization, cardiac hospitalization, death/transplant/HF hospitalization, death/transplant/cardiac hospitalization, and death/transplant/any hospitalization. Clinical . Patients with a left ventricular ejection fraction (EF) from 40% to 50% were divided into three different subgroups (see text for details). Numbers of patients are given in parenthesis. HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
outcomes after enrollment were collected by telephone interviews at home or in-person interviews at clinic visits. These were supplemented with reviews of the medical records at 6, 12, 18, and 24 months. Hospitalization for HF was defined as an admission for acute decompensated HF in the discharge summary. Cardiac hospitalization included HF exacerbations, in addition to other cardiac-related diagnosis such as acute coronary syndrome and arrhythmias. For patients who were unreachable by telephone and did not have any documentation of contact in their medical record, vital status was determined by the social security death index.
Statistical analysis
Comparisons between HFmrEF improved, HFmrEF unchanged, and HFmrEF deteriorated were conducted using ANOVA and Fisher's exact test for continuous and categorical data, respectively. For ordinal and non-normal variables, the data were summarized by the median (1 st quartile, 3 rd quartile) and compared via the Kruskal-Wallis test. Clinical outcomes were evaluated through time-to-event analyses. Kaplan-Meier curves were created by for each group and compared using the log-rank test. The start time was the date of entry into the HF registry. Patients were followed until first event occurrence or last follow-up. After an overall significant finding, pairwise comparisons of the Kaplan-Meier curves were made with an adjustment for multiple testing based on the Tukey-Kramer method.
In order to evaluate clinical outcomes, HFmrEF improved and HFmrEF deteriorated patients were age-(±5 years) and gender-matched to HFrEF (EF <40%) and HFpEF (EF >50%) patients contemporaneously enrolled in the registry. A Cox proportional hazards model was built to determine the risk of each outcome for each group. A shared frailty model approach was used to account for the matching. The matched datasets were combined so that the 
Results
Of the 1086 patients enrolled in the Washington University Heart Failure Registry, 172 had an LVEF between 40-50% at the time of enrollment ( Figure 1) . Review of the electronic medical records revealed that four of the HFmrEF patients did not have known prior LVEF, and were therefore excluded from further analysis. Of the remaining 168 HFmrEF patients, 123 (73%) had a previous LVEF <40% (EF 2.9 ± 2.4 years prior to enrollment), 29 (17%) had a previous LVEF >50% (EF 3.3 ± 2.6 years prior to enrollment), and . 
Demographics and clinical characteristics of heart failure with mid-range ejection fraction patients
The demographics of the entire cohort of HFmrEF patients at the time of entry into the registry, as well as the three subgroups of HFmrEF patients are outlined in Table 1 . As shown, the age for the entire cohort of HFmrEF patients was 55.6 ± 13.1 years, with 54% male patients, 76% Caucasian and 24% African Americans. The major co-morbidities for the HFmrEF group included hypertension (51%), hyperlipidaemia (35%), diabetes (26%), coronary artery disease (25%), obstructive sleep apnoea (21%) and chronic obstructive pulmonary disease (9%). The distribution of NYHA functional class for the HFmrEF cohort was: 18% class I, 61% class II, 18% class III, and 4% class IV. The baseline demographics for the HFmrEF improved, HFmrEF unchanged, and HFmrEF deteriorated were relatively well matched, with the exception that there 
HFmrEF, heart failure with mid-range ejection fraction. was a significantly greater prevalence of a history hypertension in the HFmrEF deteriorated group (P = 0.043). However, systolic and diastolic blood pressures were not different among the HFmrEF subgroups at the time of enrollment. The aetiology of HF for the entire cohort of HFmrEF patients, as well as the three subgroups of HFmrEF patients is summarized in Table 2 . As shown, the vast majority of the patients in the HFmrEF group were comprised of patients with idiopathic dilated cardiomyopathy (65%), followed by ischaemic heart disease (20%). Table 3 summarizes the echocardiographic data for the HFmrEF group of patients, as well as the three subgroups of HFmrEF patients. The mean EF at enrollment for the entire HFmrEF group was 45 ± 3.6%. There was no difference in mean LVEF in the three different subgroups of patients. Of note, the prior LVEF for the HFmrEF improved group was 25 ± 7.7%, which represented a ∼20% improvement in LVEF. The prior LVEF for the HFmrEF deteriorated group was 57 ± 4.9%, which represented ∼12% decline in LVEF. The mean LV end-diastolic dimension (LVEDD) for the HFmrEF cohort was 5.4 ± 0.7 cm, whereas the mean LV end-systolic dimension (LVESD) was 4. were no differences in LVEDD among the three subgroups of HFmrEF patients; however, LVESD in HFmrEF patients with a deteriorated LVEF was significantly less (P = 0.022) than for HFmrEF recovered. The prevalence of diastolic dysfunction by Doppler echocardiography was 76% for the entire HFmrEF cohort. Interestingly, when we examined the degree of diastolic dysfunction in the HFmrEF improved group vs. the HFmrEF deteriorated group, there was a significantly greater degree of diastolic dysfunction in the HFmrEF deteriorated group, implying that the underlying pathophysiology of the HFmrEF group is heterogeneous ( Figure 2 ).
9 Table 4 summarizes the medications for the entire HFmrEF patient cohort, as well as the three HFmrEF subgroups. Overall, the use of evidence-based medical therapies was very high for the entire cohort, with 88% of the patients on beta-blockers, 86% of the patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 42% of the patients on an aldosterone receptor blocker. The majority of the patients were on loop diuretics (69%). There was no difference in the medication use between the three HFmrEF groups; however, there was a trend towards greater digoxin use in HFmrEF Figure 2 Degree of diastolic dysfunction for heart failure patients with a mid-range ejection fraction (HFmrEF) based on origin ejection fraction. Among patients with diastolic dysfunction, the percentage of HFmrEF improved, HFmrEF unchanged, and HFmrEF deteriorated patients with grade I, II, and III diastolic dysfunction 9 is illustrated. Overall, there was a statistically significant increase in the degree of diastolic dysfunction in patients with more preserved ejection fractions at origin compared to those with reduced ejection fraction at origin (P < 0.001 based on Fisher's exact test).
improved patients and a trend towards more calcium channel blocker use in HFmrEF deteriorated patients ( Table 4) . Figure 3 summarizes the clinical outcomes of the entire HFmrEF cohort compared with age-and gender-matched HFrEF patients (n = 102) and age-and gender-matched HFpEF patients (n = 82). The salient finding shown in Figure 3A shows Figure 3B shows that the composite of time to death, cardiac transplantation and cardiac hospitalization was not significantly different (P = 0.27) in the HFmrEF patients compared with the HFpEF patients. We next compared the clinical outcomes for the three different subgroups of HFmrEF patients. Figure 4A shows that the HFmrEF improved subgroup had significantly (P = 0.011) improved freedom from death/transplant/cardiac hospitalization in comparison to the HFmrEF deteriorated population. This difference was led by time to first cardiac hospitalization (P = 0.029) as illustrated in Figure 4B . Further, there was no significant difference (P = 0.40) between groups for the time to first HF hospitalization (data not shown). Figure 5 shows a forest plot that compares multiple clinical outcomes for the HFmrEF improved patients compared with ageand gender-matched HFrEF patients (n = 71) and HFmrEF deteriorated patients compared with age-and gender-matched patients with HFpEF (n = 16). This analysis shows that there was a significant (P = 0.01) 70% improved freedom from death in HFmrEF improved patients compared with HFrEF patients, whereas there was a non-significant (P = 0.95) 11% increase in mortality risk for the HFmrEF deteriorated patients compared with HFpEF patients. Similarly, both risk of cardiac hospitalization and the composite of death, cardiac transplantation and all-cause hospitalization were significantly improved in the HFmrEF improved group [79% (P < 0.001) and 60% (P < 0.001), respectively] compared with HFrEF patients, whereas risk of cardiac hospitalization and the composite of death, cardiac transplantation and all-cause hospitalization were not significantly different in the HFmrEF deteriorated patients compared with HFpEF patients [8% (P = 0.90) and 64% (P = 0.32) increased risk, respectively]. Additionally, the risk of cardiac hospitalization in HFmrEF improved vs. HFrEF was found to be different than that found in HFmrEF deteriorated vs. HFpEF (HR 0.21 in HFmrEF improved vs. HFrEF compared with HR 1.08 respect to clinical management, insofar as they have not been studied in clinical trials. 3 The ESC HF guidelines, however, do recognize this as a distinct group of patients defined by their mid-range EF and having positive natriuretic peptide levels with relevant structural heart disease or diastolic dysfunction. 7 The results of this study, in which we examined the epidemiology, pathophysiology and clinical outcomes of a contemporary group of HF patients with an LVEF of 40-50%, suggest that HFmrEF patients are a heterogeneous group of patients comprised of at least three different subsets. As shown in Figure 1 , HFmrEF patients represented ∼16% of all patients enrolled in the Washington University Heart Failure Registry. We 
Clinical outcomes
P-value
Worse Outcome Improved Outcome Figure 5 Forest plot of clinical outcomes for heart failure patients with mid-range ejection fraction (HFmrEF) compared with heart failure patients with reduced (HFrEF) or preserved ejection fraction (HFpEF). The hazard ratios (HR) and 95% confidence intervals (CI) comparing clinical outcomes of death, time to first cardiac hospitalization and the composite of time to death/cardiac transplantation/all cause hospitalization for: HFmrEF improved patients (n = 71) compared with age-and gender-matched HFrEF patients (n = 71); and HFmrEF deteriorated (n = 16) patients compared with age-and gender-matched HFpEF patients (n = 16). All P-values represent the significance of the HRs for HFmrEF improved patients compared with matched HFrEF patients or for HFmrEF deteriorated patients compared with matched HFpEF patients. further sub-classified HFmrEF patients into three different subgroups based on their prior LVEF, namely patients with a previous LVEF <40% (HFmrEF improved), patients with a prior LVEF >50% (HFmrEF deteriorated), and patients with a previous LVEF between 40-50% (HFmrEF unchanged). Consistent with a prior report, 1 the majority of the patients in this study were classified as HFmrEF improved (73%), whereas 17% of the patients were classified as HFmrEF deteriorated, and only 10% were categorized as HFmrEF unchanged (Figure 1) . Table 1 shows that the demographics of the HFmrEF population reflected whether the patient's LVEF improved or deteriorated when compared to their prior assessment of LV function. The demographics of the HFmrEF improved subgroup revealed a greater prevalence of male patients and a greater prevalence of patients with coronary artery disease, consistent with the known demographics of HFrEF patients. In contrast, the HFmrEF deteriorated subgroup was comprised of more females with hypertension and atrial fibrillation/flutter, consistent with the known demographics of patients with HFpEF. Another, important observation in the present study is that the HFmrEF deteriorated patients had significantly more advanced diastolic dysfunction by Doppler echocardiography when compared with the HFmrEF improved subgroup of patients (Figure 2) , which may reflect the greater prevalence of a history of hypertension in the HFmrEF deteriorated patients.
A second important observation of this study is that the clinical outcomes of patients with HFmrEF were directly related to whether prior EF was depressed (<40%) or preserved (>50%).
. That is, the cohort of HFmrEF improved patients had significantly better clinical outcomes relative to age-and gender-matched patients with HFrEF ( Figure 5 ), as well as improved clinical outcomes relative to HFmrEF deteriorated patients ( Figure 4) . In contrast, the clinical outcomes of the HFmrEF deteriorated subgroup of patients were not significantly different from ageand gender-matched HFpEF patients ( Figure 5) . Importantly, the HFmrEF improved and HFmrEF deteriorated patients were receiving similar evidence-based medical therapies, suggesting that the differences in clinical outcomes in the subgroups were not necessarily the result of the use of more evidence-based medical therapies in the HFmrEF improved patients. Viewed together, the results of this study suggest that in a contemporaneous population of HF patients, patients with a mid-range LVEF between 40-50% are remarkably heterogeneous with respect to demographics, pathophysiology, and HF clinical events.
Heart failure with mid-range ejection fraction
The current management of patients with HF is guided by categorizing patients based on their EF at the time of presentation: namely, HFrEF, defined in the literatures as an EF ≤35% or ≤40%, or HFpEF, defined in the literature as an EF ≥40%, 45%, 50%, or 55%. 2 More recently a third group of HF patients with LVEFs that range from 40-50% has been recognized as a unique "intermediate group", whose pathophysiology is unclear. 2 Although the nomenclature for this intermediate group has not been formalized, the term HF with a mid-range, borderline or between EF has been used previously, 7,10 -12 and herein the acronym HFmrEF has been employed in order to remain consistent with the current nomenclature of HFrEF and HFpEF. Surprisingly, very little is known with regard to the population of HFmrEF patients. The extant literature suggests that the HFmrEF population is comprised of patients whose demographics lie somewhere in between those of HFpEF and HFrEF patients, but in aggregate are more similar to those of HFpEF patients, and are comprised of more female patients with a history of hypertension and a history of atrial fibrillation/flutter. 10, 11, 13 However, HFmrEF patients have an increased burden of coronary artery disease burden when compared with HFpEF patients. Furthermore, the literature suggests that HFmrEF patients receive similar medications to those used for HFrEF and HFpEF patients, with HFrEF patients using more digoxin, angiotensin converting enzyme inhibitors, angiotensin receptor blockers and HFpEF patients using more calcium channel blockers than HFmrEF patients. Beta-blocker use is similar in all of the groups that were studied. 10, 11, 13 Of note, prior studies suggest that the clinical outcomes for HFmrEF patients are distinct from those of HFrEF and HFpEF. A 5-year follow-up of HFmrEF patients showed that all-cause mortality was increased when compared to patients with HFpEF, but was significantly less than patients with HFrEF, 12, 14 whereas HFmrEF mortality at 1 year after hospital discharge was similar to that of HFpEF. 10, 11, 13 All-cause re-hospitalization and HF re-hospitalization were less in HFmrEF and HFpEF patients compared with HFrEF. 10, 14 In the present study, we observed similar trends in clinical outcomes in the HFmrEF patients when compared to age-and gender-matched HFpEF and HFrEF patients (Figure 3 and Supplementary material online, Tables S2 and S2).
The present study both confirms and extends the extant literature with respect to HFmrEF in several important respects. First, the results of this study show that >90% of the HFmrEF patients either had a prior LVEF <40% that improved on evidence-based medical therapy, or had prior LVEF >50% that deteriorated for unknown reasons. Thus, the overwhelming majority of patients categorized as "HFmrEF" do not represent a distinct and/or unique group of HF patients, but rather represent a heterogeneous group of HFrEF and HFpEF patients, in whom a change in LVEF resulted in their being categorized as being a unique intermediate subset of HF patients. Viewed within this context, the striking improved clinical outcomes in HFmrEF patients compared with age-and gender-matched HFpEF patients in this ( Figure 3A ) and prior studies, 12, 14 likely represents the well-recognized difference in clinical outcome between responders (i.e. patients whose LVEF improved) and non-responders to medical therapy. In this regard, it is equally interesting to note that patients with HFmrEF continue to have significant number of HF events, including death, and that the magnitude of these events was not significantly different from patients with HFpEF. The observation that HFmrEF patients with an improved LVEF continue to have recurrent HF events is consistent with prior reports which have shown that recovery of LV function is not necessarily associated with freedom from future HF events. 15 This study has a number of limitations that warrant discussion. First, clinical registries suffer from a number of limitations including referral biases, as well as inherent limitations on the types of data that are collected. In this regard, since we did not record longitudinal studies of LV function, we performed a retrospective review of echocardiograms that were performed prior to enrollment of patients into the registry, and we only included those patients whose EF could be confirmed. Second, there is no consensus on the appropriate definition for the cut-off value for EF for patients with HFrEF, HFmrEF and HFpEF, and different studies have used different cut-offs. 10, 11, 13, 14 Here we used a range of EFs between 40-50% to define the HFmrEF population, which is similar to the range of values defined as intermediary by the American Heart Association.
2 Lastly, the numbers of patients in the HFmrEF deteriorated and HFmrEF unchanged group were relatively small, which may have precluded the ability to discern statistically significant differences in these subgroups.
Conclusions
Patients with HFmrEF represent a growing proportion of patients who are encountered in clinical practice. Here we show that obtaining information with regard to the historical course of the patient's prior LVEF allows one to identify a distinct pathophysiological substrate and clinical course for this heterogeneous group of patients. Given what is currently known with regard to the clinical course of HFrEF patients who respond to medical therapy, the observation that the HFmrEF improved patients had better clinical outcomes compared with age-and gender-matched patients with HFrEF is probably not surprising. However, an important finding in this study is that the HFmrEF improved patients have clinical event rates of death, cardiac transplantation and cardiac hospitalization that are similar to those observed in HFpEF patients. Thus, the HFmrEF improved patients still have clinical HF despite a significant recovery of LV function. While this study does not address the issue of whether the HFmrEF improved patients should be maintained on evidence-based medical therapies for HF after their EF is >40%, the observation that HFmrEF patients still have significant HF events would argue against stopping their medications. Although the HFmrEF deteriorated patients represented a relatively smaller proportion of patients in this study, our results suggest that these patients have a pathophysiological substrate that overlaps patients with HFpEF, and therefore suggests that this subgroup of HFmrEF patients may not respond to medical therapies that are currently used for patients with HFrEF. Further studies will be necessary to address this question. Apart from the clinical significance of the above findings, the results of this study suggest that we may have reached an inflection point in the modern era of HF therapeutics with respect to relying only on LVEF to categorize the pathophysiology of HF, and that we need to establish a new taxonomy for classifying HF patients that leverages the advances in biomedical science and incorporates the underlying molecular and environmental causes of HF in concert with the conventional assessment of LV structure and function.
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Additional Supporting Information may be found in the online version of this article: Table S1 . Washington University Heart Failure Registry patient characteristics. Table S2 . Hazard ratios (unadjusted) for heart failure with borderline ejection fraction vs. matched heart failure with reduced ejection fraction. Table S3 . Hazard ratios (unadjusted) for heart failure with borderline ejection fraction vs. matched heart failure with preserved ejection fraction.
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